Allianz Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Allianz Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-70,621	Closed	-$1.42M	–	2827
2018 Q4	$1.42M	Sell	70,621 -14,756	-17%	-$325K	﹤0.01%	1890
2018 Q3	$2.12M	Buy	85,377 +6,311	+8%	+$172K	﹤0.01%	1914
2018 Q2	$2.17M	Sell	79,066 -371	-0.5%	-$11.2K	﹤0.01%	1906
2018 Q1	$2.45M	Buy	79,437 +11,271	+17%	+$363K	﹤0.01%	1834
2017 Q4	$2.44M	Buy	68,166 +10,344	+18%	+$297K	﹤0.01%	1945
2017 Q3	$1.59M	Buy	57,822 +1,537	+3%	+$37.3K	﹤0.01%	2087
2017 Q2	$1.49M	Buy	56,285 +5,672	+11%	+$126K	﹤0.01%	2089
2017 Q1	$1.05M	Buy	+50,613	New	+$1.04M	﹤0.01%	2224

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Allianz Asset Management's RVNC Position: Q1 2019 in Review

Allianz Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2019, closing a stake of 70,621 shares — an estimated $1.42M sold.

Allianz Asset Management first reported a position in RVNC in Q1 2017 and held it in 8 quarters. The position peaked at $2.45M in Q1 2018. 112 funds tracked by Wall St. Rank hold RVNC as of Q1 2019.

Allianz Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Allianz Asset Management sold 70,621 Revance Therapeutics, Inc. shares in Q1 2019, an estimated $1.42M.
Allianz Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2017 and held it in 8 quarters.
Allianz Asset Management's Revance Therapeutics, Inc. position peaked at $2.45M in Q1 2018.
112 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2019.

Based on Allianz Asset Management's 13F filing for Q1 2019, filed 13 May 2019.